NEUROBLASTOMA RECURRENT
Clinical trials for NEUROBLASTOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new NEUROBLASTOMA RECURRENT trials appear
Sign up with your email to follow new studies for NEUROBLASTOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo therapy for childhood cancers enters human trials
Disease control Recruiting nowThis study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…
Matched conditions: NEUROBLASTOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated May 17, 2026 11:38 UTC
-
New hope for kids with rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests an experimental oral drug called AMXT 1501 combined with another drug, eflornithine (DFMO), in children and young adults up to age 21 with certain cancers like neuroblastoma, brain tumors, and sarcomas. The first part finds the safest dose, and the second part ch…
Matched conditions: NEUROBLASTOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated May 17, 2026 11:33 UTC
-
New 4-drug immune combo takes on childhood cancer
Disease control Recruiting nowThis study tests a combination of four immune-boosting treatments for children whose neuroblastoma has returned or not responded to standard therapy. The therapy includes natural killer cells, an antibody, two immune-stimulating proteins, and a drug that activates a special recep…
Matched conditions: NEUROBLASTOMA RECURRENT
Phase: PHASE2 • Sponsor: Hong Kong Children's Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for kids with Tough-to-Treat neuroblastoma: immune booster added to chemo
Disease control Recruiting nowThis study tests whether adding an experimental immune-boosting drug (N-803) to standard chemo-immunotherapy can help children and young adults whose neuroblastoma has returned or not responded to treatment. About 54 participants will receive the combination to see if it is safe …
Matched conditions: NEUROBLASTOMA RECURRENT
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 14, 2026 12:04 UTC